2010
DOI: 10.1002/14651858.cd007958.pub2
|View full text |Cite
|
Sign up to set email alerts
|

Angiogenesis-inhibitors for metastatic thyroid cancer

Abstract: Background Systemic cytostatic therapies for advanced, metastatic thyroid carcinomas have been poorly e ective. Tumor growth and metastasis depend on blood supply and blood vessel formation (angiogenesis). Therefore, inhibition of angiogenesis may represent a promising target for cancer therapy. Objectives To evaluate the benefits and risks of angiogenesis-inhibitors for metastatic thyroid cancer when given alone, or in combination with chemotherapy or radiotherapy.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
9
0
1

Year Published

2010
2010
2021
2021

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 15 publications
(10 citation statements)
references
References 39 publications
0
9
0
1
Order By: Relevance
“…In addition to that, the American Thyroid Association Guideline suggests the combination of surgery, radioactive iodine ablation, and chemotherapy may improve outcomes in ATC. Because of the high aggressiveness of ATC, previous study has suggested that vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), fibroblast growth factor receptor (FGFR), and hepatocyte growth factor receptor (HGFR/c-Met) in ATC are associated with clinical features of the disease [ 5 ]. Multikinase TKIs of lenvatinib, cabozantinib, vandetanib, and sorafenib that target VEGFR, PDGFR, FGFR, KIT, and RET pathways are the four target therapy drugs approved by the Food and Drug Administration (FDA) for advanced thyroid cancer [ 6 ].…”
Section: Introductionmentioning
confidence: 99%
“…In addition to that, the American Thyroid Association Guideline suggests the combination of surgery, radioactive iodine ablation, and chemotherapy may improve outcomes in ATC. Because of the high aggressiveness of ATC, previous study has suggested that vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), fibroblast growth factor receptor (FGFR), and hepatocyte growth factor receptor (HGFR/c-Met) in ATC are associated with clinical features of the disease [ 5 ]. Multikinase TKIs of lenvatinib, cabozantinib, vandetanib, and sorafenib that target VEGFR, PDGFR, FGFR, KIT, and RET pathways are the four target therapy drugs approved by the Food and Drug Administration (FDA) for advanced thyroid cancer [ 6 ].…”
Section: Introductionmentioning
confidence: 99%
“…Many studies have reported the presence of endothelial cell proliferation in thyroid tumors being associated to increased expression of proangiogenic factors; therefore, identification of the profile of pro-angiogenic factors expressed and their relationship with other tumor biomarkers may help to provide novel and additional therapeutic targets. Indeed, many preclinical studies have been performed and clinical trials are in progress using novel small molecules provided with antiangiogenic activity [17][18][19].…”
Section: Discussionmentioning
confidence: 99%
“…Агресивність карцином ЩЗ корелює з посиленим ангіогенезом, а також експресією рецепторів: VEGF -VEGFR, фактора росту тромбоцитів Platelet-derived growth factors (PDGF) -Platelet-derived growth factors receptor (PDGFR), фактора росту фібробластів (FGF) -FGFR, EGF -EGFR та HGFc-Met (що стимулює або стримує ангіогенез) [64]. VEGF та його основний рецептор VEGFR-2 надекспресуються в DTC і залучені до посилення агресивності та прогресування пухлини.…”
Section: метастази пухлин щитоподібної залозиunclassified